Thursday, September 23, 2010 10:14:43 PM
Other than this, I have no idea. Just a turd with wings::
XTL Biopharmaceuticals Ltd. Completes Acquisition Of Bio-Gal
Wednesday, 4 Aug 2010 04:29pm EDT
XTL Biopharmaceuticals Ltd. announced that their purchase of Bio-Gal was completed. Under the terms of the purchase, XTL has obtained the exclusive license for the rights to a use-patent on Erythropoietin for the treatment of multiple myeloma patients, against an allocation of approximately 69% of its shares. Furthermore, XTL obtained USD1.5 million, which was raised from Bio-Gal's shareholders and private investors.
XTL Biopharmaceuticals Ltd. Completes Acquisition Of Bio-Gal
Wednesday, 4 Aug 2010 04:29pm EDT
XTL Biopharmaceuticals Ltd. announced that their purchase of Bio-Gal was completed. Under the terms of the purchase, XTL has obtained the exclusive license for the rights to a use-patent on Erythropoietin for the treatment of multiple myeloma patients, against an allocation of approximately 69% of its shares. Furthermore, XTL obtained USD1.5 million, which was raised from Bio-Gal's shareholders and private investors.
Recent XTLB News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 08:11:21 PM
- XTL Announces Receipt of Staff Delist Determination from Nasdaq • GlobeNewswire Inc. • 05/22/2026 08:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 09:09:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 12:10:18 PM
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2026 08:34:40 PM
- Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key • AllPennyStocks.com • 04/29/2026 08:21:50 PM
- XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth • IH Market News • 04/29/2026 02:47:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 01:07:41 PM
- XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies • GlobeNewswire Inc. • 04/29/2026 12:58:51 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:01:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/20/2026 08:11:31 PM
- XTL Biopharmaceuticals Announces ADS Ratio Change • GlobeNewswire Inc. • 03/20/2026 08:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 08:05:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2026 09:34:26 PM
- XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing • GlobeNewswire Inc. • 02/27/2026 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/24/2026 09:05:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2026 09:05:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/17/2026 09:05:16 PM
- XTL Update on Recent Developments • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/28/2026 01:58:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2026 09:15:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2026 09:15:09 PM
- XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency • GlobeNewswire Inc. • 01/23/2026 09:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/13/2026 09:05:32 PM
